grant

Exploring the membrane-related components of HIV-1 Env for immunogen design

Organization BOSTON CHILDREN'S HOSPITALLocation BOSTON, UNITED STATESPosted 24 Jul 2023Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoVAnimal ModelAnimal Models and Related StudiesAntibodiesAntibody ResponseAntigenic DeterminantsAntigensB blood cellsB cellB cellsB-Cell ActivationB-CellsB-LymphocytesB-cellBindingBinding DeterminantsBinding SitesBlood SerumCOVID-19 virusCOVID19 virusCellular biologyCoV-2CoV2Combining SiteComplexCytoplasmic DomainCytoplasmic TailDataEpitopesEvolutionGlycansGlycoproteinsGoalsHIV Envelope Glycoprotein gp120HIV Envelope Protein gp120HIV env Protein gp120HIV-1HIV-1 vaccineHIV-IHIV1HIV1 vaccineHTLV-III gp120HistoryHu-mABsHumanHuman Immunodeficiency Virus Type 1Human immunodeficiency virus 1Ig GenesImmune responseImmunoglobulin GenesInvestigatorsLaboratory miceLengthMembraneMessenger RNAMiceMice MammalsModern ManModificationMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryMurineMusPeptidesPharmaceutical AgentPharmaceuticalsPharmacologic SubstancePharmacological SubstancePolysaccharidesProductionPropertyProtein EngineeringProteinsR-Series Research ProjectsR01 MechanismR01 ProgramRNA vaccineRNA-based vaccineReactive SiteRecombinantsRecording of previous eventsResearchResearch GrantsResearch PersonnelResearch Project GrantsResearch ProjectsResearchersSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SerumSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2StructureSurfaceTM DomainTestingTransmembrane DomainTransmembrane RegionVaccinationVaccinesVirionVirus ParticleWorkWuhan coronavirusactivated B cellscell biologyconformationconformationalconformational stateconformationallyconformationscoronavirus disease 2019 viruscoronavirus disease-19 virusdesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccineexperiencegenetic protein engineeringgp120gp120 ENV Glycoproteingp120(HIV)hCoV19historieshost responsehumAbshuman mAbshuman monoclonal antibodieshuman monoclonalsimmune system responseimmunogenimmunogenicityimmunoresponseinnovateinnovationinnovativeinsightmRNAmRNA vaccinemRNA-based vaccinemembermembrane structuremodel of animalnCoV2neutralizing antibodynext generationnovelpharmaceuticalprogramsprotein designrational designresponsevaccine developmentvaccinology
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Summary
Structural insights from our recent work provide a strong scientific premise for exploring the membrane-related

components of HIV-1 envelope glycoprotein (Env), including the membrane proximal external region (MPER),

the transmembrane domain (TMD) and the cytoplasmic tail (CT), for vaccine development. Our data indicate

that all these regions influence the stability and antigenicity of the Env ectodomain. Major broadly neutralizing

antibody (bnAb) epitopes on HIV-1 Env include CD4 binding site, V1V2-glycan, V3-glycan, the fusion

peptide/gp120-gp41 interface and the MPER. The optimal presentation of these epitopes, critical for their

antigenicity and immunogenicity, depends on the Env trimer organization and conformation. Recently, the fusion

peptide-based immunogens have induced robust cross-clade neutralizing responses in animal models,

suggesting that bnAbs may be elicited by vaccination. In this research project, our central hypothesis is that

rationally designed HIV-1 Env immunogens in different conformations with various degrees of bnAb epitope

exposure induce different B cell responses, which may lead to production of diverse bnAbs in animal models

and to new strategies for HIV-1 vaccine immunogen design. The research team is formed by a group of

outstanding investigators with diverse yet complementary expertise to carry out the proposed studies. This group

has extensive experience in protein engineering, production and characterization, in B cell biology and

vaccinology in animal models, and in detailed analysis of vaccine-elicited antibody responses. The group

members have an extensive history of working together on HIV-1 and SARS-CoV-2 related projects. The team

will capitalize on the newly determined structures of the membrane-related components of HIV-1 Env to develop

two innovative immunogen-design strategies: (1) soluble Env trimer immunogens and (2) membrane-bound

intact Env trimer immunogens. We propose two Specific Aims to test the hypothesis: Aim 1. We will design,

characterize and produce Env-based immunogens in both the protein and mRNA forms and perform structural

studies of Env-based immunogens and their complexes with antibodies. Aim 2. We will evaluate immunogenicity

of novel Env-based protein immunogens and mRNA vaccines in VelocImmune human antibody mice.

Grant Number: 5R01AI174938-03
NIH Institute/Center: NIH

Principal Investigator: Bing Chen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →